Compare · MDLN vs SOLV
MDLN vs SOLV
Side-by-side comparison of Medline Inc. (MDLN) and Solventum Corporation (SOLV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and SOLV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $51.51B, about 3.5x SOLV ($14.68B).
- MDLN has been more active in the news (17 items in the past 4 weeks vs 3 for SOLV).
- MDLN has more recent analyst coverage (25 ratings vs 21 for SOLV).
- Company
- Medline Inc.
- Solventum Corporation
- Price
- -
- -
- Market cap
- $51.51B
- $14.68B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- 2024
- News (4w)
- 17
- 3
- Recent ratings
- 25
- 21
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Medline launches right-sized Ranpak packaging solutions in two key distribution centers
- SEC Form EFFECT filed by Medline Inc.
- Medline Inc. announces pricing of secondary offering of Class A common stock
- Chief Legal Officer Liberman Alexander M. was granted 798,680 units of Class B Common Stock, increasing direct ownership by 352% to 1,025,603 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. was granted 520,127 units of Class B Common Stock, increasing direct ownership by 207% to 771,197 units (SEC Form 4)
- Chief Commercial Officer Golwas Douglas P was granted 895,512 units of Class B Common Stock, increasing direct ownership by 164% to 967,560 units (SEC Form 4)
- Chief Executive Officer Boyle James M was granted 2,516,260 units of Class B Common Stock, increasing direct ownership by 7,591% to 1,869,921 units (SEC Form 4)
- Medline Inc. announces launch of secondary offering of Class A common stock
- SEC Form S-1 filed by Medline Inc.
Latest SOLV
- SEC Form 10-Q filed by Solventum Corporation
- Solventum Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Solventum Reports Third Quarter 2026 Financial Results
- Solventum Announces FDA 510(k) Clearance for Combined Use of Restrata™ Matrix and Solventum™ V.A.C.® Therapy*
- Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026
- Chief Executive Officer Hanson Bryan C converted options into 67,261 shares and covered exercise/tax liability with 26,468 shares, increasing direct ownership by 28% to 185,515 units (SEC Form 4)
- Solventum to Participate in the 2026 Wells Fargo Healthcare Conference
- SEC Form 4 filed by SVP, Controller & CAO Zieselman Neil Craig
- SEC Form 3 filed by new insider Zieselman Neil Craig
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For